ev3: The Virtues of Focus

Six years ago, ev3 was launched aiming at a broad attach on cardio- and endovascular disease. But the company found including coronary devices in its mix too difficult and too costly. Instead, the company shifted directions three years ago, with a focus on peripheral and neurovascular disease. In the process, it hopes to address what it calls "the innovation gap," the lack of devices developed specifically for the PVD and neurovascular specialists.

More from Innovation

More from In Vivo